Pharma Payment Types Explained — PlainPharmaWatch Guide

Not all payments are the same. Understanding the difference between research grants, consulting fees, speaking honoraria, and a catered lunch helps you interpret what the data actually means.

Research Payments

Research payments are made under a formal research agreement — typically a clinical trial protocol or investigator-initiated study. These are usually the largest payments by dollar value in Open Payments data, often constituting more than half of all reported dollars. A phase III clinical trial might involve millions of dollars paid to a research institution, with the principal investigator listed as recipient.

Research payments are generally considered the most legitimate category. Clinical trials are essential to drug development, and physicians who run them provide a genuine scientific service. However, research relationships can still create bias: physicians who conduct trials for a company tend to be more favorable toward that company's products in subsequent publications and prescribing.

Research payments are broken into two sub-types in CMS data: payments associated with research agreements (the largest) and payments for non-research-based purposes. Research payments to institutions (teaching hospitals) appear separately from payments to individual physicians.

Consulting Fees

Consulting fees compensate physicians for their expertise and advisory services. Common consulting arrangements include:

Advisory board participation: Physicians review a company's clinical strategy, provide feedback on trial design, or evaluate data.
Market research: Paid interviews or surveys about prescribing practices and patient needs.
Medical affairs consulting: Ongoing advisory relationships with a company's medical or clinical team.
Product development input: Feedback on device design, drug formulation, or dosing regimens.

Consulting relationships are legal and often produce genuine value for both parties. However, critics note that the most heavily consulted physicians tend to be high-volume prescribers — which raises questions about whether consulting selection is driven by expertise or by potential marketing influence. Browse companies to see which pay the most in consulting fees.

Speaking and Honoraria Payments

Speaking payments — reported in CMS data as "Compensation for serving as faculty or as a speaker at a non-accredited and non-certified continuing education program" — are paid to physicians who present at company-sponsored promotional events. These are commonly called speaker bureau arrangements.

In a typical speaker bureau setup, a pharmaceutical company recruits a physician to present approved slide decks about a drug to other physicians at dinner or lunch events. The presenter is paid an honorarium — often $1,000 to $3,000 per event. The company selects the content, the venue, and the audience. Speaker bureau physicians may give dozens of such presentations per year.

Speaker bureau arrangements are the most controversial category in Open Payments data. Multiple studies have found that joining a speaker bureau is associated with substantially increased prescribing of the promoted drug. Critics argue these events are promotional — not educational — and that the payments are compensation for influence rather than expertise. Some academic medical centers have banned their physicians from participating in speaker bureaus. The data is searchable on our top recipients page.

Food and Beverage Payments

Food and beverage payments are the most numerous category in Open Payments — millions of individual transactions totaling hundreds of millions of dollars annually. These are the lunches and dinners that pharmaceutical sales representatives buy for physician office staff and the catered meals at promotional events.

Individual food payments are often small — under $20 per person. But because they occur at such high frequency (a busy sales rep might visit dozens of offices per month), they add up. And despite their modest size, research has found measurable effects on prescribing. A landmark 2016 study in JAMA Internal Medicine found that physicians who received a single industry meal were significantly more likely to prescribe the promoted brand-name drug over a generic equivalent.

The mechanism is believed to be social reciprocity — a universal human tendency to feel obligated to return a favor. Marketing research supports this: the pharmaceutical industry spends an estimated $1-2 billion annually on food and beverage transfers precisely because they are effective at building relationships and influencing prescribing.

Travel and Lodging

Travel and lodging payments cover transportation, hotels, and associated expenses paid by companies for physicians attending company-sponsored events — advisory boards, speaker training, national meetings, and international conferences. These are distinct from travel costs reimbursed as part of a consulting agreement, which are typically rolled into consulting fee reporting.

High-dollar travel payments often involve international destinations. Some companies have faced enforcement actions for using luxury travel as a de facto kickback to high-prescribing physicians. After the Sunshine Act, many companies tightened their travel policies to avoid appearances of impropriety.

Royalties and Licenses

Royalty payments are made to physician-inventors whose intellectual property — a drug compound, a device design, a surgical technique — is commercialized by a pharmaceutical or device company. These payments can be very large, because they are typically a percentage of product revenue. A physician who co-invented a blockbuster orthopedic implant might receive millions of dollars annually in royalties.

Royalty relationships create a different kind of conflict of interest than consulting or speaking arrangements. A physician who profits from a product's commercial success has a financial incentive to recommend that product — even when equally effective alternatives exist. Medical device royalties in particular have attracted regulatory scrutiny, as the royalty recipient is often also the physician recommending the implant to patients.

View payment type breakdowns across all companies and state-level data on PlainPharmaWatch.

Frequently Asked Questions

What is the largest category of pharma payments to doctors?

Research payments are typically the largest category by dollar value, often representing more than half of all reported payments in a given year. However, research payments are distributed among a relatively small number of physicians conducting clinical trials. By transaction count, food and beverage payments are by far the most common — millions of individual meals are reported each year across a broad base of physicians.

Is it legal for pharmaceutical companies to pay doctors?

Yes. Most physician-industry financial relationships are legal when properly structured. Consulting agreements, speaking arrangements, and research contracts are all lawful forms of compensation. What the law requires is disclosure — via the Open Payments program — not prohibition. Separate laws (the Anti-Kickback Statute and the False Claims Act) prohibit arrangements specifically designed to induce referrals for Medicare or Medicaid business, but standard advisory and research relationships are permitted.

What is a "speaker bureau" payment?

A speaker bureau payment (reported as "Compensation for serving as faculty or as a speaker at a non-accredited and non-certified continuing education program") is paid to physicians who present at company-sponsored promotional events — typically dinners or lunch sessions for other physicians. These events are organized by the company, and the physician is presenting company-approved content. Critics argue speaker bureau payments blur the line between education and promotion. Research has found that physicians who join speaker bureaus subsequently increase prescribing of the promoted drug.

What counts as a research payment vs. a consulting fee?

Research payments are tied to a formal research agreement — typically a clinical trial or study protocol — and are usually reported as payments to the institution, with the physician named as principal investigator. Consulting fees are for advisory services: attending advisory boards, providing expert feedback on drug development, or reviewing clinical data. The key distinction is that research involves generating data under a protocol, while consulting involves sharing expertise and opinion. Both are legal; both require disclosure.

Can a $20 meal really influence a doctor's prescribing?

Research suggests yes — even small, frequent payments can shift prescribing behavior. A widely cited 2016 JAMA Internal Medicine study found that physicians who received a single industry-sponsored meal (average value under $20) were significantly more likely to prescribe the promoted drug. The mechanism is thought to be reciprocity — a deeply ingrained social norm — rather than explicit quid pro quo. This is why the Sunshine Act requires disclosure of even small food and beverage transfers.

What does "royalties and licenses" mean in payment data?

A royalty payment is made when a pharmaceutical or device company uses intellectual property that a physician invented or co-developed — a drug compound, a surgical technique, or a medical device design. These payments can be very large (six or seven figures) because they are tied to commercial sales of the product. Royalty recipients are typically physician-inventors who developed the product being sold, making this category different in nature from consulting or speaking payments.

Sources

Centers for Medicare & Medicaid Services — Open Payments Program Year 2024
DeJong et al. (2016). "Industry-Sponsored Meals and Physician Prescribing Behavior." JAMA Internal Medicine.
CMS Open Payments — Payment Category Definitions and Reporting Requirements
U.S. Department of Justice — Anti-Kickback Statute enforcement guidance

This content is for informational purposes only and does not constitute medical or legal advice. Reported payments do not imply wrongdoing. Consulting, speaking, and research relationships are often lawful and clinically beneficial. Always consult your healthcare provider for medical decisions.

Understanding the Data

The information presented throughout this guide is informed by publicly available public records published by federal and state government agencies. Our database aggregates and standardizes these records to make them more accessible and easier to interpret for general audiences. When we reference specific statistics or trends, they are drawn directly from these authoritative sources unless explicitly noted otherwise.

It is important to understand the limitations of any large-scale data dataset. Records may contain errors from the original data collection process, some fields may be incomplete for older entries, and classification systems may have changed over time. Our analysis accounts for these factors by clearly labeling data vintage, flagging records with missing critical fields, and noting when temporal comparisons span methodology changes in the source data.

For readers who want to conduct their own research, we recommend going directly to the source whenever possible. federal and state government agencies provides detailed documentation on collection methodology, sampling frames, and known data quality issues. Our goal is not to replace primary sources but to make them more approachable and to highlight patterns that may not be immediately obvious when browsing raw records.

How We Analyze Data Records

Our analytical approach involves several steps designed to surface meaningful insights from large datasets. First, we clean and standardize the raw data, handling variations in naming conventions, date formats, and categorical labels. Then we compute summary statistics, distributions, and comparative benchmarks across relevant dimensions such as geography, time period, and category type.

Key metrics we examine include statistical records, geographic distributions, temporal trends. These indicators provide a multi-dimensional view of each entity in our database, allowing users to understand not just individual records but how they compare to peers, regional averages, and national benchmarks. We believe this contextual approach is far more valuable than presenting raw numbers in isolation.